Short-term recommendations have been made to the NCCN and ASCO guidelines regarding the use of granulocyte colony-stimulating factor (G-CSF), inclusive of pegfilgrastim-cbqv (Udenyca^TM, Coherus BioSciences).

Due to the COVID-19 pandemic, the updated NCCN and ASCO guidelines have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20% or higher risk of febrile neutropenia to now include those regimens with a risk of 10-20%, which includes all of the intermediate risk chemotherapy regimens.

Read Prescribing Information

NCCN Guidelines

ASCO Guidelines

Posted 5/14/2020